Core Insights - Acurx Pharmaceuticals is advancing a new clinical trial program for ibezapolstat in patients with recurrent C. difficile infection (rCDI), which has the potential to change the treatment paradigm from using two agents to one [1][2] - The company has received FDA QIDP and Fast-Track Designation, and is preparing to initiate Phase 3 international clinical trials for ibezapolstat, pending funding [1][2] - Recent Phase 2 trial results showed a 96% clinical cure rate and a 100% sustained clinical cure rate for patients treated with ibezapolstat, indicating its effectiveness in treating CDI and preventing recurrence [1][2][3] Clinical Trial Details - The new open-label trial will enroll up to 20 patients with rCDI who have had at least two recurrences in the past 12 months, with the first patient expected to enroll in Q4 2026 [1] - Acurx plans to conduct an active-controlled Phase 3 registration trial following favorable results from the initial trial, aiming for FDA approval under the Limited Population Pathway for Antibacterial and Antifungal Drugs [1][2] - The Phase 2 clinical trial included a multicenter, open-label segment and a double-blind, randomized segment, demonstrating high efficacy and safety of ibezapolstat [2][3] Efficacy and Safety - In the Phase 2a trial, 100% of patients treated with ibezapolstat were cured at the end of treatment, while the Phase 2b trial showed a 94% clinical cure rate [2][3] - The combined Phase 2 results indicated a 96% clinical cure rate, with 100% of patients remaining free of CDI recurrence for one month after treatment [2][3] - Ibezapolstat was well-tolerated, with no serious drug-related adverse events reported [2] Market Context - C. difficile infection is a significant public health issue, with approximately 500,000 infections and 30,000 deaths annually in the U.S., leading to a healthcare cost burden of around $5 billion [1][3] - The recurrence rate for CDI after treatment with standard antibiotics ranges from 20% to 40%, highlighting the unmet need for effective prevention strategies [3] - Acurx's approach with ibezapolstat aims to address this need by maintaining a healthy gut microbiome while effectively treating CDI [3]